DCPH

About Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative therapies to significantly improve outcomes for cancer patients. Their core strategy involves tackling the mechanisms of drug resistance that often limit the effectiveness and longevity of current cancer treatments, serving markets both domestically and internationally. The company's flagship product, QINLOCK, is employed in the treatment of gastrointestinal stromal tumors (GIST) and is additionally undergoing a Phase 3 clinical trial (INTRIGUE study) for second-line GIST. Deciphera's pipeline also includes vimseltinib, a potent, orally available, and highly selective switch-control kinase inhibitor targeting colony stimulating factor 1 receptor (CSF1R) for tenosynovial giant cell tumor (TGCT). Furthermore, they are advancing DCC-3116, currently in preclinical development, which targets RAS/RAF mutant cancers. Established in 2003, Deciphera Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

CEO: Steven L. Hoerter
IPO Date: Sep 28, 2017

Market Data

Open: $25.56
High: $25.61
Low: $25.56
Volume: 1.6M
Avg Volume: 1.9M
52W High: $25.61
52W Low: $9.90

Valuation

Market Cap: $2.2B
Enterprise Value: $2.2B
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$147.5M
Revenue: $163.4M
Net Income: -$194.9M
Cash: $83.5M
Debt: $25.9M

Events

EarningsMay 10

EPS est. -0.55 · actual -0.52